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OBJECTIVE: To investigate the impact of the baseline status of patients with hepatitis B virus-associated acute-
on-chronic liver failure on short-term outcomes.
METHODS: A retrospective study was conducted that included a total of 138 patients with hepatitis B virus-
associated acute-on-chronic liver failure admitted to the Department of Infectious Diseases, Taihe Hospital,
Hubei University of Medicine, from November 2013 to October 2016. The patients were divided into a poor
prognosis group (74 patients) and a good prognosis group (64 patients) based on the disease outcome. General
information, clinical indicators and prognostic scores of the patients’ baseline status were analyzed, and
a prediction model was established accordingly.
RESULTS: Elder age, treatment with artificial liver support systems and the frequency of such treatments, high
levels of white blood cells, neutrophils, neutrophil count/lymphocyte count ratio, alanine aminotransferase,
gamma-glutamyl transferase, total bilirubin, urea, and prognostic scores as well as low levels of albumin and
sodium were all significantly associated with the short-term outcomes of hepatitis B virus-associated acute-on-
chronic liver failure. The predictive model showed that logit (p) = 3.068+ 1.003  neutrophil count/lymphocyte
count ratio - 0.892  gamma-glutamyl transferase - 1.138  albumin - 1.364  sodium+ 1.651  artificial liver
support therapy.
CONCLUSION: The neutrophil count/lymphocyte count ratio and serum levels of gamma-glutamyl transferase,
albumin and sodium were independent risk factors predicting short-term outcomes of hepatitis B virus-
associated acute-on-chronic liver failure, and the administration of multiple treatments with artificial liver
support therapy during the early stage is conducive to improved short-term outcomes.
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’ INTRODUCTION
Acute-on-chronic liver failure (ACLF) refers to a group of
complex clinical syndromes characterized by acute severe
liver function damage (caused by a number of acute trigger-
ing factors) in patients with chronic liver disease, compli-
cated by the failure of one or more organs. ACLF is the most
common type of liver failure in China and has a high
mortality rate of 50-90% (1). The predominant causes of
ACLF differ in different parts of the world. In China,
the most important cause is infection with hepatitis virus,
especially hepatitis B virus (HBV) (2). The pathogenesis
of HBV-ACLF has not been well elucidated, although the
‘‘three-shock’’ hypothesis (i.e., immune injury, ischemia and
hypoxia and endotoxin-induced damage) is currently the
most generally recognized hypothesis (3).
For severe ACLF, the only effective treatment is liver
transplantation. However, due to the shortage of resources,
the demand for liver transplantation cannot be met. At present,
the treatment strategy for HBV-ACLF is comprehensive com-
bination with internal medicine, anti-viral medications and
artificial liver support therapy (4). Artificial liver supportDOI: 10.6061/clinics/2017(11)07
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therapy can temporarily replace part of the liver function and
prevent further exacerbation of liver failure by removing
toxic substances and metabolites from the serum, improving
the microenvironment for liver cell regeneration and liver
function repair. However, the efficacy of artificial liver sup-
port therapy for liver failure remains controversial (5-7).
The early identification, accurate diagnosis and prognostic
evaluation of ACLF can provide a guiding basis for active
and effective treatment. Therefore, a better understanding of
prognostic factors and more precise prognostic evaluation
systems for ACLF are in urgent need. A variety of factors
can affect the progression and prognosis of ACLF. Many
prognostic scoring systems are available for predicting the
outcomes of ACLF, including the Child-Turcotte-Pugh (CTP)
system, the model for end-stage liver disease (MELD) and
the MELD-sodium (MELD-Na). Each scoring system has
certain limitations given that not all of the influencing factors
can be included in the individual assessment. The integrated
MELD (iMELD) is a new scoring system that features the
addition of two independent ACLF prognostic risk factors,
age and serum Na levels, to the MELD scoring system (8).
In addition, the albumin-bilirubin (ALBI) grading system is a
recently developed scoring system to assess liver function (9).
Several studies have compared the predictive ability of dif-
ferent scoring systems in ACLF (10-12). Comparisons of the
predictive abilities of the CTP, MELD, MELD-Na, iMELD and
ALBI scoring systems for the prognosis of HBV-ACLF are
rarely reported. Attempts to analyze the impact of clinical
parameters and the combined prognostic abilities of these
parameters on ACLF prognosis have provided inconsistent
results due to differences in study subjects, study phases
and follow-up periods (13-15). The integration of general
information, clinical indicators and a prognostic scoring
system may better predict the short-term outcomes of patients
with HBV-ACLF.
In this study, a retrospective investigation was carried out
in HBV-ACLF patients admitted to the Department of Infec-
tious Diseases, Taihe Hospital, Hubei University of Medicine
from November 2013 to October 2016. General patient infor-
mation, laboratory indicators and prognostic scores at baseline
of HBV-ACLF patients with different prognoses were anal-
yzed, and the factors that influenced the short-term outcomes
of HBV-ACLF were investigated.
’ PATIENTS AND METHODS
Patient selection
Based on the clinical data in the medical record system of
Taihe Hospital, Hubei University of Medicine, a retrospec-
tive analysis was conducted in patients admitted to the
Department of Infectious Diseases from November 2013
to October 2016 who met the criteria of HBV-ACLF during
their hospitalization. The data from the medical records
of the selected patients were input in the form of case reports
and verified with the clinical data system in our hospital.
All of the patients were given comprehensive supportive
treatment of internal medicine after admission to the
hospital, including anti-viral therapy with nucleoside ana-
logs. Artificial liver support therapy was optional based
on the patient’s condition and willingness. The end point of
the observation in this study was the time of discharge or
in-hospital death of the patient. The study protocol was
approved by the Ethics Committee of Taihe Hospital, Hubei
University of Medicine.
Inclusion and exclusion criteria
The diagnostic criteria for HBV-ACLF were based on the
‘‘Guidelines for the Prevention and Treatment of Chronic
Hepatitis B’’ of China issued in 2015 and the ‘‘Guidelines for
Diagnosis and Treatment of Liver Failure (2012 Edition)’’ of
China. The exclusion criteria included patients complicated
with other forms of viral hepatitis, alcoholic liver disease,
autoimmune liver disease, drug-induced liver injury, asso-
ciated tumors or severe organ disease other than hepatitis B.
General information
The general information included gender, age, with/
without (w/wo) liver cirrhosis, rebound after withdrawal
of anti-viral drugs, complication with ascites at admission
and the acceptance and frequency of artificial liver support
therapy. All of this information was retrieved from the
medical record system of Taihe Hospital.
Clinical indicators
The following measurements were performed using venous
blood collected on the first day of admission or on the morn-
ing following admission: baseline white blood cell count
(WBC), absolute neutrophil count (NE), absolute lymphocyte
count (LY), NE:LY ratio (NE/LY), platelet count (PLT), levels
of alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), gamma-glutamyltransferase (GGT), albumin
(Alb), total bilirubin (TBil), urea (Urea), and creatinine (Cr),
prothrombin time (PT), prothrombin activity (PTA), acti-
vated partial thromboplastin time (APTT), the international
normalized ratio (INR) and serum Na levels. All results were
retrieved from the clinical database.
Prognostic score
The prognostic scoring systems included the CTP, MELD,
MELD-Na, iMELD and ALBI. The CTP score is the cumula-
tive result of the scores for five items (ascites, hepatic
encephalopathy, TBil, Alb and PT extension time), with
1-3 points for each item and a maximum of 15 points (16, 17).
The equation for the MELD score is as follows: 3.8 LN (TBil
[mg/dL])+ 11.2 LN (INR)+ 9.6 LN (Cr [mg/dL])+ 6.4 
cause (0 for cholestatic or alcoholic liver diseases and 1 for all
others); the result is a rounded integer (18). The equation for
the MELD-Na score is as follows: MELD+ 1.59  (135 - Na),
whereinNa is 135mmol/L if Na4 135mmol/L and 120mmol/L
if Na o 120 mmol/L (19). The equation for the iMELD score
is as follows: MELD+ (0.3  Age) - (0.7  Na)+ 100 (8).
The equation for the ALBI score is as follows: (log10TBil
[mmol/L]  0.66) + (Alb [g/L]  - 0.085) (9).
Prognostic criteria
The prognostic criteria in this study were based on
the ACLF clinical improvement criteria in ‘‘Guidelines for
Diagnosis and Treatment of Liver Failure (2012 Edition)’’
of China (2). A good prognosis needs to meet all of the
following conditions simultaneously: 1) the clinical symptoms
are significantly improved and hepatic encephalopathy has
disappeared; 2) signs of jaundice and ascites are significantly
improved; and 3) liver function is significantly improved
(TBil o5 ULN, PTA 440%). The patients who died, whose
condition became more advanced, and those who still
experienced ACLF were included in the poor prognosis
group.
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Data processing
All data included in this study were retrieved from the
electronic medical record system of Taihe Hospital and
validated using the clinical data system. Cases with missing
or incomplete data, such as AFP data, were not included in
the study.
Statistical analysis
Statistical Package for the Social Sciences (SPSS) 17.0
software was used for the statistical analysis. The measure-
ment data were first tested for a normal distribution. Data
that showed a normal distribution were represented as x–±s
and were analyzed using the t-test. The data that were not
normally distributed were represented as medians (P25 and
P75) and analyzed using the nonparametric rank sum test.
The count data among different groups were analyzed using
the w2 test. The area under the receiver operating character-
istic (ROC) curve was used to assess the predictive power of
the five scoring systems for the prognosis of HBV-ACLF, and
the cut-off value of the continuous variable was calculated.
The method of likelihood-ratio-forward-selection in non-
conditional binary logistic regression analysis was used
to obtain the independent risk factors and to establish a
predictive model. The threshold used for statistical signifi-
cance was po0.05.
’ RESULTS
Case enrollment
A total of 171 patients with HBV-ACLF were admitted to
the department of infectious disease of Taihe Hospital from
November 2013 to October 2016. A total of 138 patients were
selected according to the inclusion and exclusion criteria, includ-
ing 111 males and 27 females with an average age of 45.80±
11.01 years. There were 74 cases in the poor prognosis group,
accounting for 53.6%, and 64 cases in the good prognosis
group, accounting for 46.4%. Of the cases in the poor prognosis
group, 59 cases showed ACLF; 15 cases were in the pre-ACLF
state at admission. In the good prognosis group, the correspond-
ing numbers were 45 cases and 19 cases, respectively (Figure 1).
General information of the patients
The average age of the patients in the poor prognosis
group was significantly higher than that in the good
prognosis group (48.08±9.08 years vs. 43.16±12.44 years,
p=0.01). The number of patients who received artificial liver
support therapy and the frequencies of artificial liver support
therapy in the good prognosis group were significantly higher
than in the poor prognosis group (po0.01). There were no
significant differences between the two groups with respect to
sex, rebound after anti-viral drug withdrawal or the complica-
tions of cirrhosis and ascites (Table 1).
Figure 1 - Case screening and enrollment. No statistically significant difference was observed between the poor prognosis group and
the good prognosis group in terms of disease stage at admission.
Table 1 - General information of the patients.
Good prognosis Poor prognosis Statistics value p value
Age (years) 43.16±12.44 48.08±9.08 t0 = 2.621 0.010
Gender (male/female) 52/12 59/15 w2 = 0.05 0.822
W/wo liver cirrhosis 19/45 32/42 w2 = 2.707 0.100
W/wo drug-withdrawal rebound 6/5 10/22 w2 = 1.035 0.309
W/wo ascites 41/23 55/19 w2 = 1.707 0.191
W/wo ALST 54/10 36/38 w2 = 19.31 0.000
Number of treatments 1.62 (0.79, 2.55) 0.64 (0, 1.61) Z = -4.422 0.000
Note: W/wo indicates with/without; ALST is the abbreviation of artificial liver support therapy.
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The baseline clinical indicators for HBV-ACLF
patients with different prognoses
The WBC, NE, NE/LY, ALT, GGT, TBil and Urea scores/
levels were significantly higher in the poor prognosis group
(po0.05), while the Alb and Na levels in the good prognosis
group were significantly higher than in the poor prognosis
group (po0.01). There were no statistically significant dif-
ferences between the two groups in terms of the other clinical
indicators, including LY, PLT, AST, Cr, PT, APTT and INR
(Table 2).
High CTP, MELD, MELD-Na, iMELD and ALBI scores
all predict poor short-term outcomes for HBV-ACLF
patients
Compared with the patients with a good prognosis,
the patients with a poor prognosis showed significantly
higher scores for the CTP, MELD, MELD-Na, iMELD and
ALBI prognostic systems (po0.05) (Table 3). The prognosis
of HBV-ACLF was well predicted by these five types of
prognostic scores. The areas under the ROC curves of the
CTP, MELD, MELD-Na, iMELD and ALBI prognostic sys-
tems were 0.672, 0.641, 0.656, 0.699, and 0.682, respectively
(Table 4, Figure 2).
Independent prognostic factors and novel
prediction model for HBV-ACLF
The different measures of general patient information,
clinical indicators and prognostic scores at baseline for the
two groups were assigned corresponding values for non-
conditional binary logistic regression analysis. The cut-off
values of the continuous variables were calculated using the
area under the ROC curve (Tables 5 and 6) to establish the
following prediction model: logit (p) = 3.068+ 1.003  NE/
LY - 0.892  GGT - 1.138  Alb -1.364  Na + 1.651 
artificial liver support therapy. The area under the ROC
curve was 0.656, with a specificity of 64.1% and sensitivity of
62.2%. NE/LY, GGT, Alb, Na and artificial liver support
therapy were the independent factors influencing the short-
term outcomes of HBV-ACLF (Table 7).
Table 2 - Clinical indicators of the baseline status of the patients.
Good prognosis Poor prognosis Statistics value p value
WBC ( 1012/L) 5.31 (4.12, 6.79) 6.40 (4.48, 9.07) Z = -2.291 0.022
NE ( 1012/L) 3.16 (2.28, 4.99) 4.03 (2.86, 6.57) Z = -2.248 0.025
LY ( 1012/L) 1.13 (0.84, 1.43) 1.21±0.63 Z = -0.566 0.572
NE/LY 2.70 (1.79, 5.37) 3.96 (2.93, 6.69) Z = -2.517 0.012
PLT ( 1012/L) 88.0 (65.25, 125.67) 85.0 (46.0, 122.33) Z = -1.087 0.277
ALT (U/L) 507.5 (175.5, 902.0) 198.0 (81.0, 674.0) Z = -2.589 0.01
AST (U/L) 289.5 (124.0, 767.5) 210.0 (95.67, 424.0) Z = -1.543 0.123
GGT (U/L) 108.5 (62.5, 159.5) 66.0 (47.0, 125.0) Z = -2.735 0.006
Alb (g/L) 33.74±5.174 30.71±5.56 t = -3.30 0.001
TBil (mmol/L) 234.24±106.27 301.62±144.45 t0 = 3.147 0.002
Urea (mmol/L) 4.17 (2.98, 5.44) 4.54 (3.54, 7.52) Z = -2.002 0.045
Cr (mmol/L) 55.75 (42.7, 77.95) 56.95 (42.7, 85.5) Z = -0.431 0.666
Na (mmol/L) 138.91±4.209 136.07±6.33 t0 = -3.136 0.002
PT (s) 22.45 (18.5, 26.03) 25.0 (18.6, 30.9) Z = -1.738 0.082
PTA (%) 28.27 (22.64, 36.97) 26.37±12.80 Z = -1.964 0.05
APTT (s) 52.83±14.70 56.33±18.69 t0 = 1.231 0.22
INR 1.98±0.62 2.05 (1.6, 2.72) Z = -1.642 0.101
Note: Normally distributed data are represented as x–±s. Non-normally distributed data are represented as medians (P25 and P75).
Table 4 - Comparison of the five types of prognostic scores.
Area Sensitivity (%) Specificity (%) Std. error Asymptotic Sig. 95% C.I.
Lower Upper
CTP 0.672 47.3 79.7 0.045 0.000 0.593 0.761
MELD 0.641 56.8 71.9 0.047 0.004 0.549 0.733
MELD-Na 0.656 41.9 85.9 0.046 0.002 0.565 0.746
iMELD 0.699 74.3 62.5 0.045 0.000 0.611 0.786
ALBI 0.682 62.2 67.2 0.045 0.000 0.594 0.771
Logit(p) 0.656 62.2 64.1 0.046 0.002 0.565 0.746
Table 3 - Prognostic scores of the patients at baseline.
Good prognosis Poor prognosis Statistics value p value
CTP score 10.11±1.78 11.2±1.68 t = 3.706 0.000
MELD score 18.08±7.10 21.58±7.39 t = 2.828 0.005
MELD-Na score 18.95±7.7 24.18±10.11 t = 3.573 0.000
iMELD score 33.79±9.15 40.75±9.90 t = 4.268 0.000
ALBI score -1.34±0.52 -1.01±0.54 t = 3.639 0.000
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’ DISCUSSION
HBV-ACLF is a common fatal clinical disease character-
ized by a large number of necrotic liver cells, a complex
pathological mechanism and rapid progression. The results
of this study showed that many factors are closely related to
the short-term outcomes of this condition.
Age has been shown to be closely related to the severity of
liver diseases and serves as an independent prognostic factor
for end-stage liver disease (8, 20). Studies have found that the
short-term mortality rate of patients with ACLF is positively
correlated with patient age (21). In this study, the average age
of the patients with a poor prognosis was significantly higher
than that in the patients with a good prognosis, suggesting
that age is an important prognostic factor in HBV-ACLF.
As an important supportive treatment measure for the
recovery of liver function in patients with liver failure,
artificial liver therapy can improve the conditions and oppor-
tunities for the regeneration of liver cells and the recovery of
liver function. Artificial liver support systems take various
forms, and their efficacy in treating liver failure remains
controversial. Previous studies have shown that artificial
liver support therapy can only improve the bilirubin level
and hepatic encephalopathy of the patients, with no effect on
the survival rate (5). There are also studies indicating that
artificial liver support therapy can reduce the short-term
mortality rate of patients with ACLF, whereas its impact
on long-term survival is uncertain (6). Considering that the
above results are for different types of artificial liver support
therapy and different periods of application, plasma replace-
ment therapy was primarily applied in this study. The num-
ber of patients who received artificial liver support therapy
and the frequency of this therapy were significantly higher in
the good prognosis group than in the poor prognosis group.
Moreover, artificial liver support therapy was an indepen-
dent factor for the short-term outcomes of HBV-ACLF. There-
fore, the early active implementation of treatment combined
with artificial liver support therapy can significantly improve
the short-term outcomes of patients with HBV-ACLF.
WBC, NE and the NE/LY ratio are often associated with
inflammation and infection. According to the ‘‘three-shock’’
hypothesis, inflammation is an important step in the develop-
ment of HBV-ACLF (3). At the same time, studies have shown
that infection can induce and promote the development of
ACLF (22), and the severity of inflammation is significantly
correlated with the prognosis of ACLF (23) The study of Li
et al (13) showed that WBC is an independent risk factor
for HBV-ACLF. In this study, the WBC, NE count and NE/LY
ratio of the patients with a poor prognosis were significantly
higher than those of the patients with a good prognosis,
suggesting that, in addition to WBC, a high NE count
and NE/LY ratio are also important prognostic factors for
HBV-ACLF.
The following events occur in cases of liver failure: liver
cell necrosis occurs; liver function is impaired; enzyme
synthesis is reduced; disorders in detoxification, excretion
and transport capacity occur; bilirubin, amino acids and
other substances are released into the blood and accumulate;
serum bilirubin and transaminase levels increase; and the
Figure 2 - ROC curves for CTP, MELD, MELD-Na, iMELD, ALBI score
and logit (p) curve.
Table 5 - Area under the ROC curve and the cut-off value of
each variable.
Cut-off value c-statistic 95% CI
Lower Upper
Age 43.5 0.643 0.549 0.738
WBC 6.75 0.613 0.52 0.707
NE 5.635 0.611 0.517 0.705
NE/LY 2.947 0.624 0.53 0.719
ALT 127.5 0.372 0.279 0.465
GGT 76 0.365 0.272 0.457
Alb 34.85 0.343 0.252 0.435
TBil 251.2 0.632 0.54 0.725
Urea 6.365 0.599 0.505 0.693
Na 136.3 0.361 0.268 0.454
CTP 11.5 0.672 0.593 0.761
MELD 21.448 0.641 0.549 0.733
MELD-Na 25.636 0.656 0.565 0.746
iMELD 34.705 0.699 0.611 0.786
ALBI -1.119 0.682 0.594 0.771
Table 6 - Variable assignment.
Assignment
0 1
Age p 43.5 4 43.5
WBC p 6.75 4 6.75
NE p 5.635 4 5.635
NE/LY p 2.947 4 2.947
ALT p 127.5 4 127.5
GGT p 76 4 76
Alb p 34.85 4 34.85
TBil p 251.2 4 251.2
Urea p 6.365 4 6.365
Na p 136.3 4 136.3
MELD p 21.448 4 21.448
MELD-Na p 25.636 4 25.636
iMELD p 34.705 4 34.705
CTP p 11.5 4 11.5
ALBI p -1.119 4 -1.119
Artificial liver support therapy (ALST) No Yes
Prognosis Good
prognosis
Poor
prognosis
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synthesis of proteins and coagulation factors decreases,
resulting in decreased Alb levels and the development of
coagulation disorders. In the present study, liver function and
coagulation function were abnormal in both groups, and
the levels of ALT, GGT, TBil and Alb all showed significant
differences between the two groups. Of these measures, GGT
and Alb were independent risk factors for poor prognosis
of HBV-ACLF. However, a comparison of the baseline PTA of
the patients in the two groups showed a significance level of
p=0.05. Therefore, this difference was not considered statisti-
cally significant. Baseline PTA may be related to the patient’s
stage of disease at admission. Because the majority of patients
in this study had reached the ACLF state at admission, with
PTAp40%, the difference between the two groups was small.
Changes and differences in coagulation can be further
investigated and analyzed at different times and over different
observation periods.
Ascites, hyponatremia and hepatorenal syndrome are com-
mon complications of ACLF. Complications such as refractory
ascites, hyponatremia and renal injury are often interrelated
and may continuously degenerate (2). In this study, the
serum Na levels of patients in the poor prognosis group were
significantly lower than those of the patients with a good
prognosis. Low Na levels were an independent risk factor for
poor prognosis of HBV-ACLF; this finding is consistent with
the results of the studies of Zhang et al (15) and Shi et al (24).
The results suggest that electrolytes should be closely moni-
tored and electrolyte imbalances should be corrected during
HBV-ACLF treatment.
In this study, the serum levels of urea were higher in the
poor prognosis group than those in patients with good
prognoses, whereas no significant difference in the level
of Cr was found between the two groups. Accordingly,
renal function damage may have a certain relationship with
the prognosis of HBV-ACLF. However, the etiology of all
patients included in this study was HBV infection. The
diagnostic criteria for ACLF were based on the ‘‘Guidelines
for Diagnosis and Treatment of Liver Failure (2012 Edition)’’
of China. In cases of ACLF associated with HBV infection,
early organ damage is primarily manifested as liver function
damage and coagulation dysfunction rather than as increased
Cr levels.
Use of the prognostic evaluation system can help clinicians
predict disease prognosis in the early stage of the disease and
assess the severity of the disease, providing guidance in the
choice of active and effective treatment. However, because
each prognostic scoring system has limitations, this study
for the first time compared the five scoring systems (CTP,
MELD, MELD-Na, iMELD and ALBI) in HBV-ACLF patients
with differing prognosis. The results showed that all five
prognostic scoring systems demonstrated good predictive
value for ACLF. The prognostic scores of the patients at
baseline status in the poor prognostic group were significantly
higher than those of the patients in the good prognosis group,
suggesting that the prognosis of HBV-ACLF was significantly
correlated with the prognostic scores at baseline status.
A novel prognostic scoring system was established accord-
ing to the factors that affect the short-term outcomes of HBV-
ACLF, as follows: logit (p) = 3.068+ 1.003  NE/LY- 0.892 
GGT - 1.138  Alb - 1.364  Na+ 1.651  artificial liver sup-
port therapy. The sensitivity and specificity were 62.2% and
64.1%, respectively. The sensitivity of this novel predictive
model was much higher than those of MELD-Na and MELD
scores. Additionally, the area under the ROC curve of this
predictive model was much larger than that of the MELD
score, although it was smaller than that of iMELD score. Most
importantly, except for serum Na, the parameters of NE/LY,
GGT, Alb, and artificial liver support therapy were shown
to be important factors that affect the short-term outcomes
of HBV-ACLF as well. In addition to the indexes of liver
function, complications such as infection were also included in
this model. Thus, the novel predictive model was extremely
suitable for ACLF patients in the end stage with multiple
complications, especially those with an extremelyelevated
INR, and this circumstance was restricted in evaluations using
the iMELD, MELD-Na, and MELD scores.
Differences in study subjects, study phases and sample
sizes may lead to different results. Although this study was a
comprehensive study of factors that contribute to the short-
term outcomes of HBV-ACLF, it had some limitations. First,
all patients were enrolled from a single center, which may
not reflect regional influences on the prognosis. Secondly,
alpha fetal protein and a history of antiviral therapy were not
examined in this study. Lastly, only short-term outcomes
were analyzed. Multi-center studies over different observa-
tion periods are required to further research HBV-ACLF and
to provide a better theoretical basis for its clinical diagnosis
and treatment.
In conclusion, a variety of factors can affect the prognosis
of HBV-ACLF patients. Older age, high WBC, NE, NE/LY,
and TBil levels, renal dysfunction, hyponatremia, hypopro-
teinemia and high prognostic scores at baseline often suggest
a poor prognosis. For patients with HBV-ACLF, within the
context of anti-viral treatment and comprehensive internal
medicine treatment, infection control should be strengthened
and the stability of the patient’s lab values, including the
electrolyte balance, should be maintained. In addition, early
active treatment combined with artificial liver support therapy
is recommended. Further studies are needed to enhance our
understanding of HBV-ACLF pathogenesis and reduce its
morbidity and mortality.
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